TEST:

LymphoTrack® TRG Assay

We introduced new metrics in the diagnostic criteria for our TRG-NGS assay based on recurrent trends observed in challenging cases. These changes led to better agreement with visual analysis and reduced the need for reviewer intervention based on subjective interpretation.

In this cohort of PTCL patients receiving consolidative ASCT in CR1, all 4 patients with negative TCR MRD post-ASCT remain in remission at median follow-up of 32.5 months. The negative predictive value of TCR NGS MRD post-ASCT warrants further evaluation.

In this cohort of patients with PTCL receiving consolidative ASCT in CR1, all 4 pts with negative TCR MRD post-ASCT remain in remission at median follow up of 32.5 mo post-ASCT. The negative predictive value of TCR NGS MRD post-ASCT should be further evaluated. Clinical trial information: NCT03297697.

"Overall, NGS-based assessment of TCR clonality in MDS patients resulted in fewer patients interpreted as having clonal T-cell expansions compared to gel-based detection. Samples displaying TCR-clonality as detected by NGS-based methods correlated with elevated proportion of CD3+/CD57+ T-cells. Follow up studies include increase of the dataset size and correlation of clonal T-cell expansions with clinical features and response to therapy."

Subjects initiated treatment with CHOEP (n=16), BV-CHP (n=11), CHOP (n=5), CEOP (n=1) CHOP+azacitidine (n=6), CHOEP+lenalidomide (n=1), EPOCH (n=1). Measurement of peripheral blood TCR at the end of treatment is feasible in peripheral T-cell lymphomas using next generation sequencing with a known tumor clonotype. Detectable TCR at the end of treatment correlates with lack of CR but the majority of patients in complete remission by PET/CT have a detectable TCR clonotype at end of treatment. Longer follow up is required to determine if consolidative transplant alters TCR dynamics.